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• In response to an alarming second wave of COVID-19 infections, extensive new
restrictions were implemented in Melbourne, often referred to as Lockdown 2.0,
that ran at various levels from early July until city-wide Stage 4 restrictions
(including a curfew and major restrictions on movement) were introduced on the
2nd of August. These remained largely intact until late October 2020.
• The Illicit Drug Reporting System (IDRS) is an illicit drug monitoring system
which has operated in Australia since 2000, and includes annual interviews with
people who inject drugs (PWID) recruited from capital cities [1].
• In order to understand the impact of Lockdown 2.0 a second wave of IDRS
interviews was conducted from November 30 until December 22 2020 (n=100),
complementing interviews conducted around the time or just after the initial
restrictions, often termed Lockdown 1.0 (n=179).
• This output presents key findings from this Round 2 of interviews with
comparison against findings from Round 1 interviews as appropriate.
• IDRS interviews are conducted with a sentinel sample of people aged 18 or
older who have injected drugs at least once monthly in the preceding six months
and resided in Melbourne, Victoria for at least 10 of the last 12 months.
• Participants were recruited via advertisements in needle syringe programs and
other harm reduction services and via peer referral.
• In previous years, participants completed a one-hour face-to-face interview, and
were reimbursed $40 for their time and expenses.
• In 2020, interviews were completed via phone (instead of face-to-face) and
participants were reimbursed electronically to manage risk of COVID-19
transmission.
• The interview length was reduced and the content adapted to include COVID-19
specific items, anchored to implementation of restrictions in Australia at the
beginning of March 2020 (Round 1) or July 2020 (Round 2).
• The study protocol and recruitment methods remained otherwise unchanged.
Findings are suppressed where ≤5 participants report an outcome to protect
confidentiality.
• The Round 2 2020 Victorian IDRS sample characteristics were similar to those
recruited in 2019 and in earlier years, being mostly male (59%) with a median
age of 44 years (IQR 38-48). One in ten (11%) participants from Round 2
reported participating in Round 1. The Round 2 sample was similar to Round 1
(61% male, mean age 42), aside from median weekly income which was
reported at $450 (IQR=400-500) in Round 2, compared to $533 in Round 1
(IQR=450-550; p<0.001). Drug use characteristics in Round 2 were also
consistent with Round 1, with the majority (71%) reporting heroin as the drug of
choice (72% in Round 1), as well as the drug injected most in the last month
(64%; 70% in Round 1); and 73% reporting weekly or more frequent use of
heroin (75% in Round 1).
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• 50% of participants reported that they had been tested for COVID-19, up from
20% in Round 1. As with Round 1, none reported having been diagnosed with
COVID-19.
• 17% of participants reported that they were worried about getting COVID-19 at
the end of the successful lockdown 2.0, down from 59% interviewed during
lockdown 1.0.
• At the time of Round 2 interviews, 88% reported wearing a facemask and 74%
reported using hand sanitiser/ washing hands more frequently but only 48%
reported they had been social distancing in the past month (down from 87% in
Round 1).
• The distribution of concerns related to the COVID-19 pandemic in Figure 1
showed a largely similar pattern across the two rounds of data collection.
• 12% of participants reported that they had been given new shelter/short term
housing or put up in a hotel since July, compared to 8% in Round 1 (asked
about the lockdown 1.0 period, from March 2020).
• Around one-quarter (26%) reported that the income they received in the month
prior to interview was more than what they earned in June (i.e., before lockdown
2.0), 21% said less, and 53% said a similar amount.
• When asked about financial difficulties they had experienced in the four weeks
prior to interview in Round 2, 62% reported being unable to buy food or going
without meals, while 56% reported asking for help from welfare/ community
organisations, 55% for help from friends/family, and 41% reported that they
could not pay bills on time. All of these figures were higher than those found in
Round 1.
Figure 1. The percentage of the IDRS Victorian sample endorsing potential 















Limited access to naloxone/emergency treatment if overdose
Limited access to harm reduction supplies/services
Limited access to treatment
Getting sick or dying
Limited access to health services for non-COVID-19 issues
Having unstable housing
Drug withdrawal due to forced quarantine/self-isolation
Increased policing
Drug withdrawal due to limited supply/availability
Limited availability of drugs
Family/loved ones getting sick or dying
Increased cost of drugs
% of IDRS Victorian sample
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• The decline in self-reported frequency of injecting noted in Round 1 continued in
Round 2 with 22% reporting a decrease in their injecting frequency in the previous
four weeks compared to June (i.e., before lockdown 2.0).
• 12% of Round 2 participants reported that the drug they injected most during the
last month was different to the drug injected most in June. Most commonly this
change involved a shift from heroin to methamphetamine.
• Figure 2 shows the percentages of participants who reported changing their use of
specific drugs since the beginning of March 2020 (Round 1) or since July 2020
(Round 2) as compared to before. As in Round 1, most participants reported no
change in Round 2. However, 37% of those who reported recent (i.e. past six
month) heroin use and 23% of those who reported recent methamphetamine use,
reported using less since the beginning of July 2020. Frequently cited reasons
included that the drug was more expensive or less available. Of note, 31% of
those who reported recent alcohol use and 26% of those who reported recent
cannabis use reported using more since the beginning of July 2020 as compared
to before. Participants cited increased boredom and difficulties accessing other
drugs.
• 20% of Round 2 participants reported that they injected alone more since the
beginning of July 2020 as compared to before.
Figure 2. Change in drug use since March (Round 1) and July (Round 2) 2020 
amongst people who report use in the past six months. 
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• Heroin and methamphetamine were most commonly reported to have increased
in price since the beginning of July compared to before (reported by 69% and
72%, respectively).
• Reported prices of both heroin and methamphetamine increased significantly





























Round 1 Round 2
Figure 3. Median reported price of a point of crystal methamphetamine and heroin 
for Round 1 and Round 2 data collections.
• Patterns of reports of purity of key drugs were largely similar in the two Rounds
(Figure 4), but the percentage reporting decreased purity of heroin was higher in
Round 2 compared to Round 1, with a majority reporting a reduction in purity
since the beginning of July 2020.
• Most participants reported the availability of drugs to be stable (Figure 5). The
percentage reporting stable availability of methamphetamine was higher in Round
2 compared to Round 1.
Figure 4. Change in perceived purity of heroin and crystal methamphetamine 
since the beginning of March (Round 1) and July (Round 2) 2020 compared to 
before. 
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*p<0.050; **p<0.010; ***p<0.001 for Round 2 versus Round 1.
Figure 5. Change in perceived availability of select illicit drugs since the 
beginning of March (Round 1) and July (Round 2) 2020 compared to before. 
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Note. Estimates for non-prescribed oxycodone, morphine, methadone syrup and cannabis (bush) were collected but are 





• After Lockdown 2.0 Round 2 participants were asked about their use of drug
treatment in the past 6 months, with 13% reporting being in drug treatment since
July, and 57% before and since, a pattern similar to that found in Round 1.
• Of those in treatment since July, 74% reported any disruption in that period. Most
commonly, reported disruptions included appointments via phone (67%) and
changed hours of service (18%).
• Of those Round 2 participants who reported being on opioid agonist therapy
(OAT) since July (n=69), approximately half (48%) reported an increase in take-
away doses, and 21% a decrease in pharmacy doses, but there was no change
in urine drug testing reported (Figure 6). Further, among those in OAT since the
beginning of July, 9% reported changing their OAT type to buprenorphine depot
injections.
• Most Round 1 participants reported that their satisfaction with their drug
treatment was the same compared to before March (85%), while 9% said better
and 6% said worse. Two-thirds (66%) of Round 2 participants reported their
satisfaction with treatment compared to before July was the same, 28% said
better and 7% said worse.
• 10% of Round 2 participants reported difficulties accessing needles/syringes
since the beginning of July, with 80% reporting re-using their own needles more
often as a result.
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Figure 6. Change in aspects of drug treatment since March (Round 1) and 







• Fewer participants reported experiencing an opioid overdose in the previous 12
months in Round 2 (9%) compared to Round 1 (19%, p=0.050).
• 29% of Round 2 participants reported accessing take-home naloxone for opioid
overdose reversal during the previous 12 months, with very few reporting
difficulty accessing the drug.
• 53% of Round 2 participants reported experiencing withdrawal from any drug
during the previous 12 months (5% before July, 3% since July and 45% both
before and since July), with the pattern very similar to that evident for Round 1.
• When asked about their physical health in the past 4 weeks compared to June
(i.e., before lockdown 2.0), 17% reported it as better, 63% reported it as similar,
and 20% reported it as worse, a pattern very similar to that found in Round 1.
• When asked about their mental health in the past 4 weeks compared to June,
19% reported it as better, 49% reported it as similar, and 32% reported it as
worse, a pattern very similar to that found in Round 1.
• The IDRS sample recruited after Lockdown 2.0 in Melbourne was similar to 
samples previously recruited, except for a reduction in reported income. This 
may be partially explained by the drop in the jobseeker payment in 
September 2020 from $1100 to $800 per fortnight.
• Despite major restrictions on movement and gathering, most participants in 
Melbourne reported little change in their illicit drug use during Lockdown 2.0, 
although changes in use varied by drug with change most evident in relation 
to heroin use. Injecting frequency declined during Lockdown 2.0. Perceptions 
of illicit drug availability were mostly that it remained stable or became harder 
to access. Prices of heroin and methamphetamine were shown to increase.
• Most participants rated their mental and physical health as similar compared 
to before July, and concerns about the impact of COVID itself were reduced 
compared to Lockdown 1.0. Overdose was reported by few participants. 
• Of those in drug treatment, a majority of participants reported disruptions to 
their drug treatment since July, and most participants reported that their 
satisfaction with their drug treatment was the same compared to before July.
• Reported engagement in criminal behaviour did not vary over Lockdown 1.0 
and  Lockdown 2.0, but more than one in ten participants reported receiving 
a fine for violation of COVID restrictions, which is much higher than reported 
among the wider population. 
• The IDRS interviews were conducted with a sentinel sample of people who 
inject drugs and results are not representative of injecting drug use more 
widely.
• It is critical to monitor impacts of COVID-19, particularly among those who 
report more regular or dependent use of drugs (e.g. through interviews 
involving the ongoing SuperMIX cohort of people who regularly inject drugs)
• More extensive findings on COVID-19 impacts will be reported in future 
outputs from the project. 
• 51% of Round 2 participants reported any crime in the past month, a similar
pattern to that found in Round 1. Most commonly this was property crime
(34%), followed by drug dealing (32%).
• A greater number of participants in Round 2 reported being the victim of a
violent crime in the past month (19%) than in Round 1 (10%; p=0.054).
• Of those who commented in Round 2 (n=72), 14% reported receiving a fine for
not following COVID directives during the second lockdown (i.e., stay-at-home,
self-isolation, mask wearing, curfew).
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